Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LORI J WIRTH

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1750344008
CMS profile
261486
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$34,100.14

57 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $14,508.41 32
Eisai Co., Ltd. $9,914.24 14
Merck Sharp & Dohme Corporation $6,568.12 8
Genentech USA, Inc. $2,075.00 1
Bayer HealthCare Pharmaceuticals Inc. $900.00 1
Exelixis Inc. $134.37 1

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LORI J WIRTH

NPI 1750344008 · CMS profile ID 261486

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750344008?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LORI J WIRTH, NPI 1750344008, CMS profile ID 261486. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750344008?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LORI J WIRTH, NPI 1750344008, CMS profile ID 261486. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750344008?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LORI J WIRTH, NPI 1750344008, CMS profile ID 261486, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750344008?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

57 matching records · $34,100.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 57 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–57 of 57.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Co., Ltd. $235.1908/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697047937 CMS
Eisai Co., Ltd. $172.2308/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697047939 CMS
Eisai Co., Ltd. $826.6908/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697047941 CMS
Eli Lilly and Company $1,597.0606/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657955741 CMS
Eli Lilly and Company $1,500.0006/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657966069 CMS
Bayer HealthCare Pharmaceuticals Inc. $900.0005/23/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628478771 CMS
Genentech USA, Inc. $2,075.0005/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 857133077 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34,100.14 57
PY2020 $36,215.78 26
PY2021 $27,775.00 13
PY2022 $57,182.43 35
PY2023 $66,247.01 42
PY2024 $10,246.33 7
PY2025 $49,202.42 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $957.13 2
PY2025 Principal investigator $153,866.16 7
PY2024 Recipient $1,165.00 1
PY2024 Principal investigator $577,386.39 15
PY2023 Recipient $2,860.50 2
PY2023 Principal investigator $1,681,861.78 121
PY2022 Recipient $655.00 1
PY2022 Principal investigator $1,336,141.10 20
PY2021 Recipient $655.00 1
PY2021 Principal investigator $1,430,363.90 10
PY2020 Recipient $23,300.00 1
PY2020 Principal investigator $997,359.12 18
PY2019 Principal investigator $659,044.60 86

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

9 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ascendis Pharma Endocrinology Inc $8,850.00 08/12/2025 Covered Recipient Teaching Hospital
Dana-Farber Cancer Institute
BelieveIT-201 No dispute reported 06/30/2026 1233996647
Recipient Regeneron Pharmaceuticals, Inc. $556.91 05/14/2025 Covered Recipient Physician A MULTICENTER, PHASE 2, OPEN-LABEL STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS PEMBROLIZUMAB IN SUBJECTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA No dispute reported 06/30/2026 1184123956
Principal investigator 1 Novartis Pharmaceuticals Corporation $894.18 03/27/2025 Non-covered Recipient Entity
DANAFARBER CANCER INSTITUTE
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients with locally advanced or metastatic, radio-active iodine refractory BRAFV600E mutation-positive No dispute reported 06/30/2026 1190305969
Principal investigator 1 Eli Lilly and Company $84,092.00 02/21/2025 Non-covered Recipient Entity
DANA FARBER PARTNERS CANCER CARE INC
A PHASE 1/2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001) No dispute reported 06/30/2026 1187880317
Principal investigator 1 Ascendis Pharma Endocrinology Inc $34,500.00 01/30/2025 Non-covered Recipient Entity
Dana-Farber/Mass General Brigham Cancer Care, Inc.
BelieveIT-201 No dispute reported 06/30/2026 1233994412
Recipient Regeneron Pharmaceuticals, Inc. $400.22 01/24/2025 Covered Recipient Physician A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1B CLINICAL STUDY OF CMP-001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS A MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA No dispute reported 06/30/2026 1184123954
Principal investigator 1 Eli Lilly and Company $14,415.74 01/16/2025 Non-covered Recipient Entity
DANA FARBER PARTNERS CANCER CARE INC
A PHASE 1 STUDY OF ORAL LOXO-260 IN PATIENTS WITH RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION REFRACTORY TO SELECTIVE RET INHIBITORS No dispute reported 06/30/2026 1187881306
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,794.24 01/15/2025 Non-covered Recipient Entity
MASSACHUSETTS GENERAL HOSPITAL
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients with locally advanced or metastatic, radio-active iodine refractory BRAFV600E mutation-positive No dispute reported 06/30/2026 1190298385
Principal investigator 1 Eli Lilly and Company $9,320.00 01/07/2025 Non-covered Recipient Entity
DANA FARBER PARTNERS CANCER CARE INC
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 1187879735